RxDoctor Payments Data

Jitesh Vachhani, MD

Internal Medicine · Bristol, CTNPI 1205815487

Payments from drug & device makers

$2,495in general payments, 2019–2025

Across 34 payments — averaging $73.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$921
  • Boehringer Ingelheim$423
  • GSK$250
  • Lilly USA, LLC$247
  • Novo Nordisk$192
  • Insulet Corporation$127
  • plus $335 from 4 others

What the payments were for

  • Food & beverage$2,34394%
  • Education$1516%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,495 in reported general payments places this provider in the 85th percentile of 2,067 internal medicine providers in Connecticut.

See all internal medicine providers in Connecticut

Medicare billing

Part B allowed, 2024
$109,108
Medicare patients
189
Services billed
865

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin71$74,382
EliquisApixaban52$61,968
MounjaroTirzepatide43$55,612
OzempicSemaglutide36$47,719
JanumetSitagliptin Phos/Metformin Hcl39$46,437
JanuviaSitagliptin Phosphate27$44,861
XareltoRivaroxaban15$23,543
TradjentaLinagliptin18$15,791
MyrbetriqMirabegron13$11,569
Diclofenac Sodium25$4,836
Rosuvastatin Calcium204$3,959
Atorvastatin Calcium418$3,680
Esomeprazole Magnesium36$3,346
Naproxen32$2,917
Lantus SolostarInsulin Glargine,hum.Rec.Anlog17$2,884

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$423$90,17489 claims
Lilly USA, LLCMounjaro$247$55,61243 claims
Novo NordiskOzempic$192$47,71936 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,067 internal medicine providers in Connecticut.

Other internal medicine in Bristol

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →